New drug Kylo-11 aims to tackle stubborn heart disease risk factor
Disease control
Recruiting now
This phase 2 trial tests Kylo-11, an experimental drug, in 204 adults with heart disease and high levels of lipoprotein(a) – a genetic risk factor for heart attacks and strokes. Participants receive either Kylo-11 or a placebo injection for about a year. The main goal is to see i…
Phase: PHASE2 • Sponsor: Kylonova (Xiamen) Biopharma co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC